David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...
Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...
We will continue to offer access to personalized treatments as allowed by law to meet patient needs,” Hims & Hers CEO said.
Clinical trials have found that people who are on the prescription for a year can lose more than 10% of their body weight.
The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper compounded versions ...
The long-running U.S. shortage of Novo Nordisk's blockbuster weight loss ... stock closed about 5% higher on Friday. Meanwhile, shares of Hims & Hers, a telehealth company offering compounded ...
Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.
A small study confirms observations what users have observed: the medications reduce their cravings for alcohol.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback